Last reviewed · How we verify

NCT06630156

The Present Study Was Conducted to Evaluate Bioceramic Root Repair Material Versus Bio MTA in Revascularization of Immature Young Permenant Teeth.

Active, enrolled Phase 2 Last updated 15 October 2024
What this trial tests

Phase 2 trial testing Revascularization of Immature Young Permenant Teeth in Revascularization of Immature Young Permenant Teeth in 28 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
21 August 2022
Primary endpoint
21 November 2024
21 December 2024

Quick facts

Lead sponsorAl-Azhar University
PhasePhase 2
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment28
Start date21 August 2022
Primary completion21 November 2024
Estimated completion21 December 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

Adults 7 to 12, any sex, with Revascularization of Immature Young Permenant Teeth. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present clinical study wasdirected to evaluate bioceramic root repair material versus Bio MTA in Revascularization of Immature Young Permenant Teeth through: 1. Clinical evaluation including: Pain, swelling, sinus or fistula, mobility and crown discoloration. 2. Radiographic evaluation including: Root lengthening, continued thickening of the dentinal walls, apical closure and regression of the peri-apical lesion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Revascularization of Immature Young Permenant Teeth

Currently open trials in the same condition.

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06630156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing